Vulnerable populations are individuals or groups for whom special protection is required when participating in clinical research. Vulnerability can result from a limited capacity to make a free, informed decision, a special health situation or the circumstances of emergency care. It means neither a general exclusion from research nor a reduced worthiness of protection, but requires a scientifically and ethically particularly justified inclusion.
Protection concept in clinical trials
The protection of the rights, safety, dignity and well-being of the participants takes priority over the interests of science and society. For vulnerable individuals, the general informed consent and benefit-risk assessment is therefore not sufficient. The protocol, information documents and conduct must consider the specific protective situation. Protective measures must fit the respective situation and may not be replaced by blanket assumptions about an entire group. The ethics committee assesses whether selection, information, consent process, trial procedures and safety monitoring meet the additional need for protection. The sponsor must traceably justify the measures in the protocol and in the documents. In case of changes in the risk situation, they must be reassessed during the trial. This includes appropriate representation, understandable information, the minimization of burden and a procedure that avoids undue influence.
The Declaration of Helsinki requires a fair and responsible inclusion of vulnerable individuals, groups and communities. Research should be responsive to their health needs and priorities. It should not be conducted in a less vulnerable group, unless inclusion is just not required or exclusion would exacerbate existing inequalities. This does not imply a blanket non-consideration, but requires a specific scientific justification and appropriate protective measures.
Classification according to Regulation (EU) No 536/2014
Chapter V of the Regulation contains special rules for four explicitly regulated situations. First, additional requirements apply to incapacitated subjects according to Article 31, in particular the informed consent of the legally designated representative and the consideration of any explicit wish of the subject. Second, Article 32 regulates minors with separate requirements for information, participation and additional protection.
Third, Article 33 contains requirements for pregnant or breastfeeding subjects. The trial must have the potential to produce a direct benefit for the pregnant or breastfeeding woman concerned, or her embryo, foetus or child, or have the potential to produce a benefit for other pregnant or breastfeeding women or for reproductive health, provided that risk and burden are minimal and the requirements of the Regulation are met. Fourth, Article 35 permits inclusion in emergency situations under narrowly defined conditions without prior informed consent, if prior informed consent cannot be obtained and the other legal requirements are fulfilled.
Differentiation from consent of minors
The term vulnerable populations describes the overarching protection concept and the various situations regulated in the Regulation. The consent of minors, on the other hand, deals with the specific process of consent by the legally designated representative, child-appropriate information and assent. Minors are thus a specially protected group, but not the only group for which additional requirements apply.
Vulnerability is also not to be equated with incapacity to give informed consent. Pregnant or breastfeeding women can be capable of giving informed consent and still require the special material prerequisites of Article 33. For emergency patients, the focus is on the temporal impossibility of prior informed consent. For each situation, the sponsor must apply the appropriate regulation instead of using vulnerability merely as a general label.
Relevance for clinical trials
Already during trial planning and feasibility, it must be checked whether the target population triggers special protection requirements. This concerns the scientific justification, the benefit-risk section, the selection of qualified investigational sites, the information documents and the ethics application. During conduct, consent pathways, burden minimization, reporting of new safety information and the documentation of the participant’s will are critical to quality.
Full-service CROs such as Mediconomics support the regulatory classification of the target population, the preparation of protocol-compliant consent documents, submission to authorities and ethics committees as well as the training and monitoring of investigational sites. Regulatory affairs, medical writing, clinical operations and monitoring can transfer the special protective measures into the protocol, site processes and source documentation.
Frequently Asked Questions (FAQ)
Are vulnerable individuals excluded from clinical trials?
No. Inclusion is possible if it is scientifically justified and the respectively applicable additional protection requirements are met. A blanket exclusion can prevent relevant findings precisely for these groups.
Which groups does Chapter V of the Regulation systematically regulate?
It contains special articles on incapacitated subjects, minors, pregnant or breastfeeding subjects as well as emergency situations.
Is every pregnant participant incapacitated to give informed consent?
No. The special regulation for pregnancy and breastfeeding is based on the special protective situation for woman, embryo, foetus or child, not on a general incapacity to give informed consent.
Regulatory references
- Regulation (EU) No 536/2014, Chapter V and Articles 31 to 35 – contains special protection requirements for the regulated participant groups and emergencies.
- ICH E6(R3) Good Clinical Practice – requires a risk-based trial approach focused on the protection of participants.
- ICH E11(R1) Clinical Investigation of Medicinal Products in the Pediatric Population – specifies ethical protective measures for children in trials.
- Declaration of Helsinki of the World Medical Association – requires additional protective measures and fair inclusion of vulnerable individuals, groups and communities.